Press Releases

Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford. The funding supports the development of an oral formulation for Adenovirus-vectored vaccines. The project, led by Professor Dame Sarah Gilbert at the University of Oxford’s Pandemic Sciences Institute, aims to address the limitations of in

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Novo Nordisk, a leading global healthcare company headquartered in Denmark. This partnership aims to address one of the most critical challenges in modern drug development: the efficient oral delivery of therapeutic peptides. A research team will be formed to work on this challenge with support from BioMed X and Novo Nordisk. The new project, en

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is

Tonix Pharmaceuticals Holding Corp, a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual (under the tongue) formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatme

Pilatus Biosciences, Inc., a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Roche. Under the terms of the agreement, Roche will provide atezolizumab (Tecentriq®), its anti-PD-L1 therapy, to support Pilatus’ upcoming first-in-human Phase 1 trial evaluating PLT012 in combination with atezolizumab in patients with hepatocellular carcinoma (HCC). PLT012

AbbVie today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. This expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical manufacturing capabilities and capacity. Active pharmaceutical ingredient manufacturing is a complex and multi-step process t

Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. As part of the collaboration, Sartorius will invest up to 3 million US dollars in a minority shareholding in Nanotein Technologies to support the commercialization and joint development of solutions based on its NanoSpark® platform. Under the exclusive distribution agreement, Sar

ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP Adeno-Associated Virus (AAV) manufacturing services at its 128,000 sq. ft. state-of-the-art facility in Hopewell, New Jersey. This strategic expansion is designed to meet growing industry demand for high-quality viral vector production and reflects ProBio's ongoing commitment to supporting the advancement of life-changing gene therapies

As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an initiative of the MedSurplus Alliance. This collaboration reflects our broader ESG strategy and strengthens LabConnect's role as the world's most agile and responsible central laboratory services provider. Through this partnership, LabConnect will work with sponsors and clinical sites to identify and

ViruSure, a global leader in pathogen safety testing for biopharmaceuticals, and Oxford Nanopore Technologies (“Oxford Nanopore”) (LSE: ONT), the company behind a new generation of molecular sensing technology based on nanopores, today announce the launch of the industry’s first Good Laboratory Practice (GLP) validated adventitious viral agent (AVA) detection test using nanopore-based sequencing technology. The ViruSure test has been developed and evaluated under r